Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Peter_Miller
|
| gptkbp:countryOfOrigin |
gptkb:Norway
|
| gptkbp:focus |
nasal drug delivery
|
| gptkbp:foundedYear |
2000
|
| gptkbp:founder |
gptkb:Helene_Djupesland
gptkb:Per_Djupesland |
| gptkbp:headquartersLocation |
Yardley, Pennsylvania, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
OptiNose
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:product |
gptkb:ONZETRA_Xsail
gptkb:Xhance |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:OPTN
|
| gptkbp:technology |
bi-directional nasal delivery system
|
| gptkbp:therapeuticArea |
migraine
ear, nose, and throat diseases |
| gptkbp:website |
https://www.optinose.com/
|
| gptkbp:bfsParent |
gptkb:William_J._Doyle
|
| gptkbp:bfsLayer |
6
|